Esperion Therapeutics, Inc. announced today that it has priced an underwritten public offering of 30,000,000 shares of its common stock at a public offering price of $2.50 per share. The offering includes a 30‑day option for the underwriters to purchase up to an additional 4,500,000 shares. The gross proceeds from the offering, before underwriting discounts, commissions, and offering expenses, are expected to be approximately $75.0 million.
The offering is expected to close on or about October 9, 2025, subject to customary closing conditions. Piper Sandler & Co. and Cantor Fitzgerald & Co. are acting as joint book‑running managers, while Citizens JMP Securities, H.C. Wainwright & Co., and Needham & Company are acting as co‑managers. The shares are being offered pursuant to a shelf registration statement that was filed with the SEC on April 18, 2025 and declared effective on April 29, 2025 (File No. 333‑286631). The offering will be made only by means of a written prospectus and prospectus supplement that form part of the registration statement.
The proceeds from the offering will provide Esperion with additional capital to support its commercial growth, product development, and strategic initiatives. By raising approximately $75 million, the company aims to strengthen its balance sheet and fund future expansion plans, including continued commercialization of its oral, non‑statin therapies and potential pipeline development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.